NZ335276A
(en)
|
1996-10-18 |
2000-09-29 |
Vertex Pharma |
Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
|
US6608027B1
(en)
|
1999-04-06 |
2003-08-19 |
Boehringer Ingelheim (Canada) Ltd |
Macrocyclic peptides active against the hepatitis C virus
|
PE20011350A1
(es)
|
2000-05-19 |
2002-01-15 |
Vertex Pharma |
PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
|
KR100904788B1
(ko)
*
|
2000-07-21 |
2009-06-25 |
쉐링 코포레이션 |
C형 간염 바이러스의 ns3-세린 프로테아제억제제로서의 신규한 펩티드
|
US7244721B2
(en)
*
|
2000-07-21 |
2007-07-17 |
Schering Corporation |
Peptides as NS3-serine protease inhibitors of hepatitis C virus
|
SV2003000617A
(es)
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
Inhibidores de la proteasa peptidomimetica ref. x-14912m
|
US6660731B2
(en)
|
2000-09-15 |
2003-12-09 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
EP1317448B2
(en)
|
2000-09-15 |
2011-05-04 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
GB2367816A
(en)
*
|
2000-10-09 |
2002-04-17 |
Bayer Ag |
Urea- and thiourea-containing derivatives of beta-amino acids
|
EP1343807B1
(en)
*
|
2000-12-12 |
2009-04-29 |
Schering Corporation |
Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
|
EP1404704B9
(en)
|
2001-07-11 |
2008-02-20 |
Vertex Pharmaceuticals Incorporated |
Bridged bicyclic serine protease inhibitors
|
MXPA04003825A
(es)
|
2001-10-24 |
2004-07-08 |
Vertex Pharma |
Inhibidores de serina proteasa, en particular la ns3-ns4a proteasa del virus de hepatitis c, que incorpora un sistema de anillo fusionado.
|
DE60329367D1
(de)
|
2002-01-23 |
2009-11-05 |
Schering Corp |
Verwendung bei der bekämpfung von hepatitis c virusinfektion
|
US7119072B2
(en)
|
2002-01-30 |
2006-10-10 |
Boehringer Ingelheim (Canada) Ltd. |
Macrocyclic peptides active against the hepatitis C virus
|
US7091184B2
(en)
|
2002-02-01 |
2006-08-15 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
US6642204B2
(en)
|
2002-02-01 |
2003-11-04 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
KR20110028665A
(ko)
*
|
2002-04-11 |
2011-03-21 |
버텍스 파마슈티칼스 인코포레이티드 |
세린 프로테아제, 특히 c형 간염 바이러스 ns3-ns4 프로테아제의 억제제
|
MY140680A
(en)
|
2002-05-20 |
2010-01-15 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
US20050075279A1
(en)
|
2002-10-25 |
2005-04-07 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis C virus
|
AU2011203054B2
(en)
*
|
2003-04-11 |
2012-04-26 |
Vertex Pharmaceuticals, Incorporated |
Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease
|
CN100453553C
(zh)
*
|
2003-04-11 |
2009-01-21 |
沃泰克斯药物股份有限公司 |
丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
|
DK1654261T3
(da)
*
|
2003-05-21 |
2008-01-14 |
Boehringer Ingelheim Int |
Hepatitis C-inhibitorforbindelser
|
AR044694A1
(es)
*
|
2003-06-17 |
2005-09-21 |
Schering Corp |
Proceso y compuestos intermedios para la preparacion de (1r, 2s,5s) - 3 azabiciclo [3,1,0] hexano-2- carboxamida, n- [3- amino-1- (ciclobutilmetil) - 2, 3 - dioxopropil] -3- [ (2s) - 2 - [[ [ 1,1- dimetiletil] amino] carbonilamino] -3,3-dimetil -1- oxobutil]-6,6 dimetilo
|
CN100591662C
(zh)
*
|
2003-06-17 |
2010-02-24 |
先灵公司 |
制备3-(氨基)-3-环丁基甲基-2-羟基-丙酰胺或其盐的方法和中间体
|
SG180022A1
(en)
*
|
2003-06-17 |
2012-05-30 |
Schering Corp |
Process and intermediates for the preparation of (1r,2s,5s)-6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylates or salts thereof
|
CN101724022A
(zh)
*
|
2003-07-18 |
2010-06-09 |
沃泰克斯药物股份有限公司 |
丝氨酸蛋白酶抑制剂、特别是hcv ns3-ns4a蛋白酶抑制剂
|
CA2536570A1
(en)
*
|
2003-08-26 |
2005-03-10 |
Schering Corporation |
Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus
|
AR045596A1
(es)
|
2003-09-05 |
2005-11-02 |
Vertex Pharma |
Inhibidores de proteasas de serina en particular proteasa ns3-ns4a del vhc
|
AU2004274468B2
(en)
*
|
2003-09-18 |
2009-07-23 |
Vertex Pharmaceuticals, Incorporated |
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
|
ATE497505T1
(de)
|
2003-09-26 |
2011-02-15 |
Schering Corp |
Makrocyclische inhibitoren der ns3-serinprotease des hepatitis-c-virus
|
KR20120010278A
(ko)
|
2003-10-10 |
2012-02-02 |
버텍스 파마슈티칼스 인코포레이티드 |
세린 프로테아제, 특히 hcv ns3-ns4a 프로테아제의 억제제
|
US7491794B2
(en)
*
|
2003-10-14 |
2009-02-17 |
Intermune, Inc. |
Macrocyclic compounds as inhibitors of viral replication
|
EP1944042A1
(en)
|
2003-10-27 |
2008-07-16 |
Vertex Pharmceuticals Incorporated |
Combinations for HCV treatment
|
US8187874B2
(en)
|
2003-10-27 |
2012-05-29 |
Vertex Pharmaceuticals Incorporated |
Drug discovery method
|
JP4890254B2
(ja)
|
2003-10-27 |
2012-03-07 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Hcvns3−ns4aプロテアーゼ耐性突然変異体
|
JP2007532479A
(ja)
|
2003-11-20 |
2007-11-15 |
シェーリング コーポレイション |
C型肝炎ウイルスns3プロテアーゼの脱ペプチド化インヒビター
|
JP2007513971A
(ja)
*
|
2003-12-11 |
2007-05-31 |
シェーリング コーポレイション |
C型肝炎ウイルスns3/ns4aプロテアーゼの阻害剤
|
ATE495185T1
(de)
|
2004-01-21 |
2011-01-15 |
Boehringer Ingelheim Int |
Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus
|
CA2552319C
(en)
*
|
2004-01-30 |
2012-08-21 |
Medivir Ab |
Hcv ns-3 serine protease inhibitors
|
EP2311851A3
(en)
*
|
2004-02-04 |
2011-05-25 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
|
SI1719773T1
(sl)
|
2004-02-24 |
2009-08-31 |
Japan Tobacco Inc |
Kondenzirane heterotetraciklične spojine in njihova uporaba kot inhibitorji polimeraze HCV
|
US20070049593A1
(en)
|
2004-02-24 |
2007-03-01 |
Japan Tobacco Inc. |
Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
|
US7342041B2
(en)
|
2004-02-27 |
2008-03-11 |
Schering Corporation |
3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis C virus NS3 serine protease
|
CA2557304C
(en)
*
|
2004-02-27 |
2013-08-06 |
Schering Corporation |
Ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus
|
US7192957B2
(en)
|
2004-02-27 |
2007-03-20 |
Schering Corporation |
Compounds as inhibitors of hepatitis C virus NS3 serine protease
|
US7635694B2
(en)
|
2004-02-27 |
2009-12-22 |
Schering Corporation |
Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
|
CN1946690A
(zh)
*
|
2004-02-27 |
2007-04-11 |
先灵公司 |
用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的含环丁烯二酮基团化合物
|
US7816326B2
(en)
*
|
2004-02-27 |
2010-10-19 |
Schering Corporation |
Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
|
JP4745327B2
(ja)
|
2004-02-27 |
2011-08-10 |
シェーリング コーポレイション |
C型肝炎ウイルスns3プロテアーゼのインヒビター
|
DE602005021760D1
(de)
*
|
2004-02-27 |
2010-07-22 |
Schering Corp |
Schwefelverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
|
DE602005015093D1
(de)
*
|
2004-02-27 |
2009-08-06 |
Schering Corp |
Neue verbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
|
EP1725548B1
(en)
*
|
2004-03-12 |
2015-01-14 |
Vertex Pharmaceuticals Incorporated |
Processes and intermediates for the preparation of aspartic acetal caspase inhibitors
|
AR049635A1
(es)
*
|
2004-05-06 |
2006-08-23 |
Schering Corp |
(1r,2s,5s)-n-((1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil)-3-((2s)-2-((((1,1-dimetiletil)amino)carbonil)amino)-3,3-dimetil-1-oxobutil)-6,6-dimetil-3-azabiciclo(3.1.0)hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de la hepatitis c
|
DE602005015452D1
(de)
*
|
2004-05-20 |
2009-08-27 |
Schering Corp |
Substituierte proline als hemmer der ns3-serinprotease des hepatits-c-virus
|
EP1771454B1
(en)
|
2004-07-20 |
2011-06-15 |
Boehringer Ingelheim International GmbH |
Hepatitis c inhibitor peptide analogs
|
UY29016A1
(es)
|
2004-07-20 |
2006-02-24 |
Boehringer Ingelheim Int |
Analogos de dipeptidos inhibidores de la hepatitis c
|
WO2006026352A1
(en)
|
2004-08-27 |
2006-03-09 |
Schering Corporation |
Acylsulfonamide compounds as inhibitors of hepatitis c virus ns3 serine protease
|
SG155967A1
(en)
|
2004-10-01 |
2009-10-29 |
Vertex Pharma |
Hcv ns3-ns4a protease inhibition
|
ES2373450T3
(es)
*
|
2004-10-01 |
2012-02-03 |
Scynexis, Inc. |
Derivados de ciclosporina sustituidos con 3-éter y 3-tioéter para el tratamiento y la prevención de infección por hepatitis c.
|
US7196161B2
(en)
*
|
2004-10-01 |
2007-03-27 |
Scynexis Inc. |
3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
|
US7659263B2
(en)
|
2004-11-12 |
2010-02-09 |
Japan Tobacco Inc. |
Thienopyrrole compound and use thereof as HCV polymerase inhibitor
|
GB0426661D0
(en)
*
|
2004-12-06 |
2005-01-05 |
Isis Innovation |
Pyrrolidine compounds
|
NZ563369A
(en)
*
|
2005-06-02 |
2011-03-31 |
Schering Corp |
Controlled-release formulation useful for treating disorders associated with hepatitus C virus
|
US20070021351A1
(en)
*
|
2005-06-02 |
2007-01-25 |
Schering Corporation |
Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
|
CA2610167A1
(en)
*
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Administration of hcv protease inhibitors in combination with food to improve bioavailability
|
US20060275366A1
(en)
*
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Controlled-release formulation
|
WO2006130554A2
(en)
*
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Methods of treating hepatitis c virus
|
WO2006130627A2
(en)
*
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Methods for treating hepatitis c
|
CN101212970B
(zh)
*
|
2005-06-02 |
2010-07-21 |
先灵公司 |
Hcv蛋白酶抑制剂与表面活性剂的组合物
|
WO2006130626A2
(en)
*
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Method for modulating activity of hcv protease through use of a novel hcv protease inhibitor to reduce duration of treatment period
|
WO2006130552A2
(en)
*
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Methods of treating hepatitis c virus
|
US7608592B2
(en)
*
|
2005-06-30 |
2009-10-27 |
Virobay, Inc. |
HCV inhibitors
|
TWI449711B
(zh)
*
|
2005-06-30 |
2014-08-21 |
Virobay Inc |
C型肝炎病毒(hcv)抑制劑
|
US20110104109A1
(en)
*
|
2005-07-13 |
2011-05-05 |
Frank Bennett |
Tetracyclic indole derivatives and their use for treating or preventing viral infections
|
SG166791A1
(en)
|
2005-07-25 |
2010-12-29 |
Intermune Inc |
Novel macrocyclic inhibitors of hepatitis c virus replication
|
EP1912997B1
(en)
|
2005-07-29 |
2011-09-14 |
Tibotec Pharmaceuticals |
Macrocyclic inhibitors of hepatitis c virus
|
ES2449540T3
(es)
|
2005-07-29 |
2014-03-20 |
Janssen R&D Ireland |
Inhibidores macrocíclicos del virus de la hepatitis C
|
WO2007016589A2
(en)
*
|
2005-08-02 |
2007-02-08 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
US8399615B2
(en)
|
2005-08-19 |
2013-03-19 |
Vertex Pharmaceuticals Incorporated |
Processes and intermediates
|
PL385229A1
(pl)
|
2005-08-19 |
2008-09-29 |
Vertex Pharmaceuticals Incorporated |
Sposoby i związki pośrednie
|
US7964624B1
(en)
|
2005-08-26 |
2011-06-21 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
AR055395A1
(es)
|
2005-08-26 |
2007-08-22 |
Vertex Pharma |
Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
|
ATE498630T1
(de)
*
|
2005-09-30 |
2011-03-15 |
Scynexis Inc |
Arylalkyl- und heteroarylalkyl-derivate von cyclosporin a bei der behandlung und vorbeugung einer virusinfektion
|
NZ567262A
(en)
*
|
2005-09-30 |
2011-12-22 |
Scynexis Inc |
Cyclosporin derivatives and their use for the treatment and prevention of hepatitis C infection
|
CA2624333A1
(en)
*
|
2005-10-11 |
2007-04-19 |
Intermune, Inc. |
Compounds and methods for inhibiting hepatitis c viral replication
|
WO2007056221A2
(en)
|
2005-11-03 |
2007-05-18 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
EP2392589A3
(en)
|
2005-11-11 |
2012-06-20 |
Vertex Pharmaceuticals Incorporated |
Hepatitis C virus variants
|
US7705138B2
(en)
|
2005-11-11 |
2010-04-27 |
Vertex Pharmaceuticals Incorporated |
Hepatitis C virus variants
|
AR056805A1
(es)
*
|
2005-11-14 |
2007-10-24 |
Schering Corp |
Un proceso para oxidacion para la preparcion de n- (3- amino-1- ( ciclobutilmetil) -2,3- dioxopropil ) -3-(n-(( ter-butilamino) carbonil )-3- metil- l- valil) -6,6- dimetil-3- azabiciclo (3.1.0) hexano -2- carboxamida y compuestos ralacionados
|
MX2008008350A
(es)
*
|
2005-12-22 |
2008-09-03 |
Schering Corp |
Procedimiento para la preparacion de compuestos 6,6-dimetil-3-azabiciclo-[3.1.0]-hexano y sales enantiomericas del mismo.
|
PT1966130E
(pt)
|
2005-12-23 |
2014-01-30 |
Zealand Pharma As |
Compostos miméticos de lisina modificados
|
US7816348B2
(en)
|
2006-02-03 |
2010-10-19 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
PE20080197A1
(es)
*
|
2006-02-09 |
2008-04-11 |
Schering Corp |
Combinaciones que involucran el (los) inhibidor (es) de la proteasa del hcv, y metodos de tratamiento relacionado al (los) mismos(s)
|
CL2007000361A1
(es)
*
|
2006-02-09 |
2008-01-25 |
Wyeth Corp |
Combinacion que comprende un inhibidor de la arn polimerasa del virus de la hepatitis c (vhc) y un inhibidor de la proteasa del vhc; composicion farmaceutica que la comprende; y uso de la combinacion para tratar trastornos asociados con vhc.
|
EP1991229A2
(en)
|
2006-02-27 |
2008-11-19 |
Vertex Pharmaceuticals Incorporated |
Co-crystals and pharmaceutical compositions comprising the same
|
EP1998765A2
(en)
*
|
2006-03-03 |
2008-12-10 |
Schering Corporation |
Pharmaceutical combinations of hcv-protease and -ires inhibitors
|
WO2007103934A2
(en)
*
|
2006-03-06 |
2007-09-13 |
Abbott Laboratories |
Compositions and methods of use of ritonavir for treating hcv
|
WO2007109080A2
(en)
|
2006-03-16 |
2007-09-27 |
Vertex Pharmaceuticals Incorporated |
Deuterated hepatitis c protease inhibitors
|
US20080045530A1
(en)
*
|
2006-04-11 |
2008-02-21 |
Trixi Brandl |
Organic Compounds and Their Uses
|
ES2543840T3
(es)
*
|
2006-04-11 |
2015-08-24 |
Novartis Ag |
Inhibidores espirocíclicos del VHC/VIH y sus usos
|
US20070265281A1
(en)
*
|
2006-04-11 |
2007-11-15 |
Sylvain Cottens |
Organic Compounds and Their Uses
|
US8017612B2
(en)
|
2006-04-18 |
2011-09-13 |
Japan Tobacco Inc. |
Piperazine compound and use thereof as a HCV polymerase inhibitor
|
CN101495095B
(zh)
*
|
2006-04-28 |
2013-05-29 |
默沙东公司 |
通过受控的沉淀来沉淀和分离6,6-二甲基-3-氮杂-双环[3.1.0]己烷-酰胺化合物的方法和含有其的药学制剂
|
US20080193518A1
(en)
*
|
2006-04-28 |
2008-08-14 |
Schering Corporation |
Process for the precipitation and isolation of 6,6-Dimethyl-3-Aza Bicyclo [3.1.0] Hexane-Amide compounds by controlled precipitation and pharmaceutical formulations containing same
|
US8420122B2
(en)
*
|
2006-04-28 |
2013-04-16 |
Merck Sharp & Dohme Corp. |
Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
|
WO2007136759A2
(en)
|
2006-05-19 |
2007-11-29 |
Scynexis, Inc. |
Method for the treatment and prevention of ocular disorders
|
CN101443348A
(zh)
*
|
2006-05-23 |
2009-05-27 |
Irm责任有限公司 |
作为通道活化蛋白酶抑制剂的化合物和组合物
|
CA2651762A1
(en)
*
|
2006-05-23 |
2007-11-29 |
Irm Llc |
Compounds and compositions as channel activating protease inhibitors
|
JP2009539292A
(ja)
*
|
2006-06-02 |
2009-11-12 |
ぺリション、クロード、アニー |
活性電子の管理
|
KR20090024834A
(ko)
*
|
2006-07-05 |
2009-03-09 |
인터뮨, 인크. |
C형 간염 바이러스 복제의 신규 억제제
|
EP2049474B1
(en)
|
2006-07-11 |
2015-11-04 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
EP1886685A1
(en)
|
2006-08-11 |
2008-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
|
MX2009000882A
(es)
|
2006-08-17 |
2009-02-04 |
Boehringer Ingelheim Int |
Inhibidores de la polimerasa virica.
|
CA2659461A1
(en)
*
|
2006-08-25 |
2008-02-28 |
Wyeth |
Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto
|
WO2008033389A2
(en)
*
|
2006-09-13 |
2008-03-20 |
Novartis Ag |
Macrocyclic hcv inhibitors and their uses
|
US8343477B2
(en)
|
2006-11-01 |
2013-01-01 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus
|
US7772180B2
(en)
|
2006-11-09 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7888464B2
(en)
|
2006-11-16 |
2011-02-15 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7763584B2
(en)
|
2006-11-16 |
2010-07-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8003604B2
(en)
|
2006-11-16 |
2011-08-23 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2008069917A2
(en)
|
2006-11-20 |
2008-06-12 |
Scynexis, Inc. |
Novel cyclic peptides
|
JP2010510246A
(ja)
*
|
2006-11-21 |
2010-04-02 |
スミスクライン ビーチャム コーポレーション |
アミド抗ウイルス化合物
|
TW200831084A
(en)
*
|
2006-11-21 |
2008-08-01 |
Genelabs Tech Inc |
Anti-viral compounds
|
US20100081672A1
(en)
*
|
2006-12-07 |
2010-04-01 |
Schering Corporation |
Ph sensitive matrix formulation
|
EP2121604A2
(en)
*
|
2006-12-15 |
2009-11-25 |
Schering Corporation |
Bisulfite purification of an alpha-keto amide
|
PT2121605E
(pt)
*
|
2006-12-20 |
2014-02-11 |
Merck Sharp & Dohme |
Processo para preparar (1r,2s,5s)-n-[(1s)-3-amino-1- (ciclobutilmetil)-2,3-dioxopropil]-3-[(2s)-2-[[[(1,1- dimetiletil)amino]-carbonil]amino]-3,3-dimetil-1-oxobutil]- 6,6-dimetil-3-azabiciclo[3.1.0]hexano-2-carboxamida
|
US20080188545A1
(en)
|
2006-12-21 |
2008-08-07 |
Alimardanov Asaf R |
Synthesis of pyrrolidine compounds
|
WO2008082488A1
(en)
*
|
2006-12-22 |
2008-07-10 |
Schering Corporation |
4, 5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections
|
JP5055377B2
(ja)
|
2006-12-22 |
2012-10-24 |
シェーリング コーポレイション |
[5,6−環]環形成インドール誘導体およびその使用方法
|
KR20090094154A
(ko)
|
2006-12-22 |
2009-09-03 |
쉐링 코포레이션 |
Hcv 및 관련 바이러스 감염을 치료 또는 예방하기 위한 4,5-환 환상 인돌 유도체
|
WO2008086053A1
(en)
*
|
2007-01-03 |
2008-07-17 |
Virobay, Inc. |
Hcv inhibitors
|
US8293915B2
(en)
|
2007-02-09 |
2012-10-23 |
Irm Llc |
Compounds and compositions as channel activating protease inhibitors
|
EP2463284A1
(en)
|
2007-02-27 |
2012-06-13 |
Vertex Pharmceuticals Incorporated |
Co-crystals and pharmaceutical compositions comprising the same
|
EP2134717A2
(en)
|
2007-02-27 |
2009-12-23 |
Vertex Pharmceuticals Incorporated |
Inhibitors of serine proteases
|
US20100074867A1
(en)
*
|
2007-03-23 |
2010-03-25 |
Schering Corporation Patent Department, K-6-1; 1990 |
P1-nonepimerizable ketoamide inhibitors of hcv ns3 protease
|
SG174809A1
(en)
*
|
2007-05-03 |
2011-10-28 |
Intermune Inc |
Macrocyclic compounds useful as inhibitors of hepatitis c virus
|
ES2381410T3
(es)
|
2007-05-04 |
2012-05-28 |
Vertex Pharmceuticals Incorporated |
Terapia de combinación paa el tratamiento de infecciones por VHC
|
AU2008251425A1
(en)
*
|
2007-05-10 |
2008-11-20 |
Array Biopharma, Inc. |
Novel peptide inhibitors of hepatitis C virus replication
|
CA2693997C
(en)
|
2007-08-03 |
2013-01-15 |
Pierre L. Beaulieu |
Viral polymerase inhibitors
|
TW200924751A
(en)
*
|
2007-08-29 |
2009-06-16 |
Schering Corp |
2,3-substituted indole derivatives and methods of use thereof
|
AR068108A1
(es)
|
2007-08-29 |
2009-11-04 |
Schering Corp |
Derivados azaindol 2,3-sustituidos y una composicion farmaceutica
|
TW200924780A
(en)
*
|
2007-08-29 |
2009-06-16 |
Schering Corp |
2-carboxy substituted indole derivatives and methods of use thereof
|
MX2010002407A
(es)
|
2007-08-30 |
2010-03-26 |
Vertex Pharma |
Cocristales y composiciones farmaceuticas que los comprenden.
|
PT2061513E
(pt)
|
2007-09-14 |
2011-10-17 |
Schering Corp |
Método para tratar doentes com hepatite c
|
MX2010003916A
(es)
|
2007-10-10 |
2010-05-05 |
Novartis Ag |
Espiro-pirrolidinas y su uso contra infeccion por el virus de hepatitis c (hcv) y por el virus de inmunodeficiencia humana (vih).
|
US8419332B2
(en)
*
|
2007-10-19 |
2013-04-16 |
Atlas Bolt & Screw Company Llc |
Non-dimpling fastener
|
JP5249344B2
(ja)
*
|
2007-11-16 |
2013-07-31 |
メルク・シャープ・アンド・ドーム・コーポレーション |
ヘテロ環の3位が置換されたインドール誘導体およびその使用
|
US8377928B2
(en)
*
|
2007-11-16 |
2013-02-19 |
Merck Sharp & Dohme Corp. |
3-aminosulfonyl substituted indole derivatives and methods of use thereof
|
CN101910130A
(zh)
*
|
2007-11-28 |
2010-12-08 |
先灵公司 |
制备用于形成6,6-二甲基-3-氮杂双环[3.1.0]己烷化合物的中间体的脱卤化氢方法
|
EP2234977A4
(en)
|
2007-12-19 |
2011-04-13 |
Boehringer Ingelheim Int |
VIRAL POLYMERASE INHIBITORS
|
US8202996B2
(en)
|
2007-12-21 |
2012-06-19 |
Bristol-Myers Squibb Company |
Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
|
AR071270A1
(es)
*
|
2007-12-21 |
2010-06-09 |
Schering Corp |
Proceso para la sintesis de 3- amino-3 ciclobutilmetil -2- hidroxipropionamida y uso del mismo
|
JP5574982B2
(ja)
*
|
2008-02-04 |
2014-08-20 |
イデニク プハルマセウティカルス,インコーポレイテッド |
大環状セリンプロテアーゼ阻害剤
|
AP2010005416A0
(en)
*
|
2008-04-15 |
2010-10-31 |
Intermune Inc |
Novel macrocyclic inhibitors of hepatitis c virus replication.
|
US8163921B2
(en)
|
2008-04-16 |
2012-04-24 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8044023B2
(en)
|
2008-05-29 |
2011-10-25 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7964560B2
(en)
|
2008-05-29 |
2011-06-21 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US20090306033A1
(en)
*
|
2008-06-06 |
2009-12-10 |
Keqiang Li |
Novel cyclic peptides
|
CA2724523A1
(en)
*
|
2008-06-06 |
2010-01-07 |
Scynexis, Inc. |
Novel macrocyclic peptides
|
US8901139B2
(en)
*
|
2008-06-13 |
2014-12-02 |
Merck Sharp & Dohme Corp. |
Tricyclic indole derivatives and methods of use thereof
|
CN102131813B
(zh)
*
|
2008-06-24 |
2014-07-30 |
科德克希思公司 |
用于制备基本上立体异构纯的稠合二环脯氨酸化合物的生物催化方法
|
US8188137B2
(en)
|
2008-08-15 |
2012-05-29 |
Avila Therapeutics, Inc. |
HCV protease inhibitors and uses thereof
|
AR072938A1
(es)
|
2008-08-20 |
2010-09-29 |
Southern Res Inst |
Derivados de piridina y pirimidina azosustituidos y su uso en el tratamiento de infecciones virales
|
EP2331511A1
(en)
|
2008-08-20 |
2011-06-15 |
Schering Corporation |
Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
TWI409265B
(zh)
|
2008-08-20 |
2013-09-21 |
Merck Sharp & Dohme |
經取代之吡啶及嘧啶衍生物及彼等於治療病毒感染之用途
|
US8715638B2
(en)
|
2008-08-20 |
2014-05-06 |
Merck Sharp & Dohme Corp. |
Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
US8207341B2
(en)
|
2008-09-04 |
2012-06-26 |
Bristol-Myers Squibb Company |
Process or synthesizing substituted isoquinolines
|
US8563505B2
(en)
|
2008-09-29 |
2013-10-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8044087B2
(en)
|
2008-09-29 |
2011-10-25 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
KR20110075019A
(ko)
*
|
2008-10-15 |
2011-07-05 |
인터뮨, 인크. |
치료용 항바이러스성 펩티드
|
US8283310B2
(en)
|
2008-12-15 |
2012-10-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8536114B2
(en)
*
|
2008-12-31 |
2013-09-17 |
Scynexis, Inc. |
Macrocycles
|
EP2385838A1
(en)
|
2009-01-07 |
2011-11-16 |
Scynexis, Inc. |
Cyclosporine derivative for use in the treatment of hcv and hiv infection
|
GB0900914D0
(en)
|
2009-01-20 |
2009-03-04 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
US8102720B2
(en)
*
|
2009-02-02 |
2012-01-24 |
Qualcomm Incorporated |
System and method of pulse generation
|
AR075584A1
(es)
*
|
2009-02-27 |
2011-04-20 |
Intermune Inc |
COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
|
US8193372B2
(en)
|
2009-03-04 |
2012-06-05 |
Idenix Pharmaceuticals, Inc. |
Phosphothiophene and phosphothiazole HCV polymerase inhibitors
|
JP2012523419A
(ja)
|
2009-04-08 |
2012-10-04 |
イデニク プハルマセウティカルス,インコーポレイテッド |
大環状セリンプロテアーゼ阻害剤
|
US20110182850A1
(en)
*
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
WO2010138889A1
(en)
|
2009-05-28 |
2010-12-02 |
Concert Pharmaceuticals, Inc. |
Peptides for the treatment of hcv infections
|
WO2010138791A1
(en)
|
2009-05-29 |
2010-12-02 |
Schering Corporation |
Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
|
AR077139A1
(es)
|
2009-06-23 |
2011-08-03 |
Gilead Sciences Inc |
Composiciones farmaceuticas utiles para tratar el vch
|
UY32826A
(es)
|
2009-08-04 |
2011-02-28 |
Takeda Pharmaceutical |
Compuestos heterocíclicos
|
US9284307B2
(en)
|
2009-08-05 |
2016-03-15 |
Idenix Pharmaceuticals Llc |
Macrocyclic serine protease inhibitors
|
US9156818B2
(en)
|
2009-09-11 |
2015-10-13 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
CN102741270B
(zh)
*
|
2009-09-28 |
2015-07-22 |
英特穆恩公司 |
C型肝炎病毒复制的环肽抑制剂
|
TW201116540A
(en)
*
|
2009-10-01 |
2011-05-16 |
Intermune Inc |
Therapeutic antiviral peptides
|
US20110117055A1
(en)
|
2009-11-19 |
2011-05-19 |
Macdonald James E |
Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
|
EP2503881B1
(en)
|
2009-11-25 |
2015-05-13 |
Merck Sharp & Dohme Corp. |
Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
|
BR112012014899A2
(pt)
|
2009-12-18 |
2017-03-14 |
Idenix Pharmaceuticals Inc |
composto, composição farmacêutica, método para tratar ou prevenir uma infecção por vírus de hepatite c em um sujeito, método para tratar , prevenir ou melhorar um ou mais sintomas de uma doença hepática ou distúrbio associado a uma infecção por vírus de hepatite c em um sujeito, método para inibir a replicação de um vírus em um hospedeiro, método para inibir a replicação de um vírus
|
CA2785488A1
(en)
|
2009-12-22 |
2011-07-21 |
Merck Sharp & Dohme Corp. |
Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
|
EP2536410B1
(en)
|
2010-02-18 |
2015-09-23 |
Merck Sharp & Dohme Corp. |
Substituted pyrimidine derivatives and their use in treating viral infections
|
MX2012009927A
(es)
*
|
2010-02-25 |
2012-10-05 |
Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patientenzorg |
Proceso para la preparacion de alfa-aciloxibeta-formamida amidas.
|
EP2545060B1
(en)
|
2010-03-09 |
2015-11-25 |
Merck Sharp & Dohme Corp. |
Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
|
CA2805440A1
(en)
|
2010-07-26 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
|
AU2011314168A1
(en)
|
2010-09-29 |
2013-04-04 |
Merck Sharp & Dohme Corp. |
Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
|
TW201309690A
(zh)
|
2011-02-10 |
2013-03-01 |
Idenix Pharmaceuticals Inc |
巨環絲胺酸蛋白酶抑制劑,其醫藥組合物及其於治療hcv感染之用途
|
WO2012107589A1
(en)
|
2011-02-11 |
2012-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
US9156872B2
(en)
|
2011-04-13 |
2015-10-13 |
Merck Sharp & Dohme Corp. |
2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
CA2832459A1
(en)
|
2011-04-13 |
2012-10-18 |
Merck Sharp & Dohme Corp. |
2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
US8957203B2
(en)
|
2011-05-05 |
2015-02-17 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8691757B2
(en)
|
2011-06-15 |
2014-04-08 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2013033900A1
(en)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
|
WO2013033901A1
(en)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
|
WO2013033899A1
(en)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
|
EP2755981A4
(en)
|
2011-09-14 |
2015-03-25 |
Merck Sharp & Dohme |
HETEROCYCLIC COMPOUNDS CONTAINING SILYL AND METHODS OF USING THE SAME FOR TREATING VIRAL DISEASES
|
DK2583677T1
(da)
|
2011-10-21 |
2015-01-19 |
Abbvie Inc |
Fremgangsmåder til behandling af HCV omfattende mindst to direktevirkende antivirale midler, ribavirin, men ikke inteferon
|
DK2583680T1
(da)
|
2011-10-21 |
2015-01-19 |
Abbvie Inc |
Mono (PSI-7977) eller kombinationsbehandling af DAA til anvendelse ved behandling af HCV
|
US8466159B2
(en)
|
2011-10-21 |
2013-06-18 |
Abbvie Inc. |
Methods for treating HCV
|
US8492386B2
(en)
|
2011-10-21 |
2013-07-23 |
Abbvie Inc. |
Methods for treating HCV
|
WO2013072327A1
(en)
|
2011-11-14 |
2013-05-23 |
Sanofi |
Use of boceprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
|
WO2013178682A2
(en)
*
|
2012-05-30 |
2013-12-05 |
Chemo Ibérica, S.A. |
Multicomponent process for the preparation of bicyclic compounds
|
CN103508918B
(zh)
*
|
2012-06-18 |
2015-09-09 |
上海医药工业研究院 |
带有环丁基的α-羟基β-氨基酯类化合物及其制备方法
|
WO2014053533A1
(en)
|
2012-10-05 |
2014-04-10 |
Sanofi |
Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
|
WO2014061034A1
(en)
*
|
2012-10-18 |
2014-04-24 |
Msn Laboratories Limited |
Process for preparation of boceprevir and intermediates thereof
|
SG11201502802PA
(en)
|
2012-10-19 |
2015-05-28 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
US9227990B2
(en)
|
2012-10-29 |
2016-01-05 |
Cipla Limited |
Antiviral phosphonate analogues and process for preparation thereof
|
WO2014071007A1
(en)
|
2012-11-02 |
2014-05-08 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
US9643999B2
(en)
|
2012-11-02 |
2017-05-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2914613B1
(en)
|
2012-11-02 |
2017-11-22 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
US9409943B2
(en)
|
2012-11-05 |
2016-08-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2014083575A2
(en)
|
2012-11-29 |
2014-06-05 |
Mylan Laboratories Ltd |
Improved process for the preparation of boceprevir intermediate
|
CN103936627B
(zh)
*
|
2013-01-18 |
2016-08-31 |
上海医药工业研究院 |
抗丙肝药物Boceprevir的中间体Ⅶ及其制备方法和应用
|
CN103936652B
(zh)
*
|
2013-01-18 |
2016-07-06 |
上海医药工业研究院 |
抗丙肝药物Boceprevir的中间体IV及其制备方法和应用
|
CN103936818B
(zh)
*
|
2013-01-18 |
2017-09-29 |
上海医药工业研究院 |
抗丙肝药物Boceprevir的中间体Ⅰ及其制备方法和应用
|
EP2964664B1
(en)
|
2013-03-07 |
2017-01-11 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
AR095426A1
(es)
|
2013-03-14 |
2015-10-14 |
Onyx Therapeutics Inc |
Inhibidores tripeptídicos de la epoxicetona proteasa
|
SG11201507106PA
(en)
|
2013-03-14 |
2015-10-29 |
Onyx Therapeutics Inc |
Dipeptide and tripeptide epoxy ketone protease inhibitors
|
EP2805705B1
(en)
|
2013-05-23 |
2016-11-09 |
IP Gesellschaft für Management mbH |
Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid
|
CN103387510B
(zh)
*
|
2013-08-08 |
2015-09-09 |
苏州永健生物医药有限公司 |
一种β-氨基-alpha-羟基环丁基丁酰胺盐酸盐的合成方法
|
US20160229866A1
(en)
|
2013-09-20 |
2016-08-11 |
Idenix Pharmaceuticals Inc. |
Hepatitis c virus inhibitors
|
KR20160078382A
(ko)
*
|
2013-10-24 |
2016-07-04 |
브리스톨-마이어스 스큅 컴퍼니 |
인간 면역결핍 바이러스 복제의 억제제
|
US10167298B2
(en)
|
2013-10-30 |
2019-01-01 |
Merck Sharp & Dohme Corp. |
Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof
|
EP2899207A1
(en)
|
2014-01-28 |
2015-07-29 |
Amikana.Biologics |
New method for testing HCV protease inhibition
|
US20170135990A1
(en)
|
2014-03-05 |
2017-05-18 |
Idenix Pharmaceuticals Llc |
Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
|
WO2015134560A1
(en)
|
2014-03-05 |
2015-09-11 |
Idenix Pharmaceuticals, Inc. |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
CN106810485A
(zh)
*
|
2015-11-27 |
2017-06-09 |
上海现代制药股份有限公司 |
一种手性联苯吡咯烷酮的制备方法及其中间体
|
EP3448392A4
(en)
|
2016-04-28 |
2020-01-15 |
Emory University |
ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF
|
EA201990070A1
(ru)
*
|
2016-06-21 |
2019-06-28 |
ОРИОН ОФТАЛМОЛОДЖИ ЭлЭлСи |
Производные алифатического пролинамида
|
PT3472149T
(pt)
|
2016-06-21 |
2023-11-23 |
Orion Opthalmology Llc |
Derivados de prolinamida heterocíclicos
|
JP7164521B2
(ja)
*
|
2016-06-21 |
2022-11-01 |
オリオン・オフサルモロジー・エルエルシー |
炭素環式プロリンアミド誘導体
|
WO2018073110A1
(en)
|
2016-10-20 |
2018-04-26 |
Basf Se |
Quinoline compounds as fungicides
|
EP3571190A1
(en)
|
2017-01-23 |
2019-11-27 |
Basf Se |
Fungicidal pyridine compounds
|
CN110475772A
(zh)
|
2017-04-06 |
2019-11-19 |
巴斯夫欧洲公司 |
吡啶化合物
|
ES2870106T3
(es)
|
2017-05-05 |
2021-10-26 |
Zealand Pharma As |
Moduladores de la comunicación intercelular de uniones comunicantes y su uso para el tratamiento de la enfermedad del ojo diabético
|
US20220106308A1
(en)
|
2019-02-19 |
2022-04-07 |
Univerza V Ljubljani |
Antibacterials based on monocyclic fragments coupled to aminopiperidine naphthyridine scaffold
|
US20230218644A1
(en)
|
2020-04-16 |
2023-07-13 |
Som Innovation Biotech, S.A. |
Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
|
US11351149B2
(en)
|
2020-09-03 |
2022-06-07 |
Pfizer Inc. |
Nitrile-containing antiviral compounds
|
WO2022109360A1
(en)
|
2020-11-23 |
2022-05-27 |
Enanta Pharmaceuticals, Inc. |
Novel spiropyrrolidine derived antiviral agents
|
IL307443A
(en)
*
|
2021-04-16 |
2023-12-01 |
Fujian Akeylink Biotechnology Co Ltd |
A short ring-modified peptide compound of proline and its use
|
US11970502B2
(en)
|
2021-05-04 |
2024-04-30 |
Enanta Pharmaceuticals, Inc. |
Macrocyclic antiviral agents
|
KR20240035513A
(ko)
|
2021-07-09 |
2024-03-15 |
알리고스 테라퓨틱스 인코포레이티드 |
항바이러스 화합물
|
WO2023043816A1
(en)
|
2021-09-17 |
2023-03-23 |
Aligos Therapeutics, Inc. |
Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
|
WO2023086400A1
(en)
|
2021-11-12 |
2023-05-19 |
Enanta Pharmaceuticals, Inc. |
Novel spiropyrrolidine derived antiviral agents
|
WO2023086350A1
(en)
|
2021-11-12 |
2023-05-19 |
Enanta Pharmaceuticals, Inc. |
Alkyne-containing antiviral agents
|
US11912714B2
(en)
|
2021-11-12 |
2024-02-27 |
Enanta Pharmaceuticals, Inc. |
Spiropyrrolidine derived antiviral agents
|
US11993600B2
(en)
|
2021-12-08 |
2024-05-28 |
Enanta Pharmaceuticals, Inc. |
Saturated spirocyclics as antiviral agents
|
CN114133350B
(zh)
*
|
2021-12-16 |
2023-05-23 |
浙江乐普药业股份有限公司 |
一种抗新冠药物Paxlovid中间体的制备方法
|
WO2023149981A1
(en)
*
|
2022-02-07 |
2023-08-10 |
Purdue Research Foundation |
Compounds for the treatment of sars
|
CN114736151B
(zh)
*
|
2022-04-13 |
2023-04-21 |
湖南复瑞生物医药技术有限责任公司 |
一种帕罗韦德关键中间体制备方法及化合物的结构式
|
CN115160205B
(zh)
*
|
2022-07-08 |
2024-06-07 |
上海皓鸿生物医药科技有限公司 |
一种制备(s)-1-(叔丁氧羰基)-2,5-二氢-1h-吡咯-2-羧酸及盐的方法
|